January 2017

Corporate Presentation

Strategic and Transactional Consultancy Services

for the Healthcare and Life Sciences Industry

2

The Sage Group is a leader in providing strategic transactional advice to health care companies in the pharmaceutical,

biopharmaceutical, drug delivery, diagnostics, medical device, life science, and nutraceuticals fields. We are “Strategic

Transactionalists” who have a keen understanding of defining and implementing strategy for optimal asset monetisation in a highly competitive marketplace. We have executed numerous

M&A and licensing deals over more than 20 years.

Detailed Information and our Corporate Brochure can be found at

www.sagehealthcare.com

Who Are We and What Do We Do?

3

10 Reasons to Engage Sage

The Sage Group and its Principals have experience in more than 100

substantial, multinational transactions ranging from $5-500 million in value.

We have very significant, relevant and wide-ranging experience, as a team, in

the healthcare transaction advisory business, and we get deals done.

We have direct contact with corporate business development executives

worldwide and use this network for deal facilitation.

We understand the scientific and clinical basis of healthcare companies and

employ this to communicate the key value drivers in a clear and concise fashion.

Sage Principals do the work without delegation thus bringing their experience

directly to Sage clients.

We integrate effectively with our client’s management team.

We are highly interactive, hands-on, and accountable.

We know what needs to be done to optimize positioning and we help get it done.

We know the industry, its fundamentals, and players.

We have a well-tuned process for M&A and partnering transactions making the

endeavors efficient and effective.

4

Sage Adds Value

This experience allows Sage to add value because:

We have an outstanding and proven track record in consummating

transactions, whether partnering, M&A, licensing, buy-side or sell-side or

financing

We have a strong global network second to none

We have a highly successful and productive process for buy side acquisition

searches to build pipeline and values in your company

We provide a reliable commercial development resource and support at a

cost significantly less than a full time employee and are up to speed on day 1

We have a strong and well-tuned process for M&A and partnering

transactions that makes them efficient and effective

We create a competitive environment for companies interested in your

business

Sage principals are operating executives who provide high value, senior level

strategic management

We are hands-on and accountable

We integrate effectively with our client’s Management Team

5

Sage offers a number of unique range of comprehensive features to

our clients which we believe differentiate us from other advisory firms.

Specifically: We know the needs of companies in terms of markets and growth by

acquisition and licensing

We know the needs of customers in these healthcare markets

We have extensive M&A/Licensing experience and a strong track

record in identifying targets and consummating deals

Sage knows the industry and the industry fundamentals as well as the

industry participants and has decades of deal making experience

We have strong working relationships with Corporate and VC investors

worldwide

We know how to create shareholder value through the right deals with

the right partners

Sage Unique Features

6

Recent Successes

The sale of IP assets regarding a novel antifungal technology from a Spanish

biopharmaceutical company, Palau Pharma to Actavis, now Allergan

Advised on sale of a medical technology company involved in patient vital signs monitoring to

a large US corporation

Advising EU-based oncology company on partnering of its novel chemotherapy asset

An alliance for a US biopharma company with an AU specialty pharma company for “Named

Patient” sales and registration of our client’s product in AU and NZ.

Advising EU-based medtech company on its revolutionary treatment for rhinitis

The licensing of a unique, clinically studied nutraceutical from a small Israeli company to one

of the leading global nutraceutical firms.

Advising a Danish nutraceutical microbial engineering company and their investors on

valuation and partnering/exit strategy

Sale and licensing a unique drug delivery technology from a small AU company to major

international consumer healthcare company.

The formation of an alliance to form a unique international €50M public-private venture

capital fund in Europe

Raising €6 million for an early stage European regenerative medicine company.

For a public US biopharmaceutical company, identified and negotiated a partnership in Latin

America for two research stage drugs, the first of which received approval for indications that

are much broader than in the US.

7

• Managing, negotiating and closing licensing, partnering and alliance transactions

• Strategizing and closing mergers, acquisitions and divestments on both the buy- and

sell- sides

• Global product, technology and company acquisition searches

• Strategic assessment and planning

• Market and technology assessments and due diligence

• Comparable and NPV valuations

• Investment in R&D and/or company equity through introductions, network and

facilitation.

• New ventures, interim management

• Market research: industry interviews

• Through alliances:

Regulatory advice and guidance (NDAs, BLAs, 505b2, etc)

Pricing and reimbursement in US and Europe

The Range of Services We Provide Includes

8

Sage Clients Include

Management Teams and Boards of Healthcare companies including

Pharmaceutical and Biotechnology Companies

Medical Device and Drug Delivery Companies

Nutraceutical Companies

Diagnostics Companies

Drug Discovery Companies

Life Science Research Companies

Venture Capital Investors, Institutions, Banks

Public and Private sector

Research Institutions

9

Sage planted its roots in the USA more than a decade ago

Today Sage acts for clients worldwide including:

North America, including USA and Canada

Europe, including UK, Ireland, Germany, France, Scandinavia, Hungary, Spain,

Italy, Netherlands

Israel and Middle East

Australia and NZ

Latin America

Asia, including Japan, Korea and China

Sage has offices in New Jersey, California, Florida, Cambridge (UK), Spain, Italy,

Israel and Australia

Geographical Sector Coverage

10

Principals have been CEO or COO of more than 50 Start-Ups

Senior management at more than 20 multinationals

Over 350 advisory transactional and strategic assignments

Founded over thirty ventures and startups

Identified and negotiated over 125 partnering/licensing deals

Involved in private and public financings, raising over $900 million

Led 7 IPOs on global markets

Key role in over 90 divestment/M&A transactions ranging from $10 to $500 million,

totaling over $1 billion

Cumulative transaction volume for the Principals exceeds $5 billion

Credentials

11

The Sage Group Principals

12

B.Sc. in Biophysical Chemistry, Case Western Reserve University.

PhD in Physiology and Medicine, Trinity College, University of Cambridge, UK.

Led medical research group in Cambridge for 20 years.

Founder of Life Science Resources, divested to Perkin Elmer following three key

acquisitions, financing and revenue/profit growth.

Founder of several companies in pharma, biotech, med tech, regenerative

medicine and diagnostics which have been financed, grown and exited

successfully.

NXC/NXD of a portfolio of healthcare and life science businesses, private and

public with experience of IPOs and VC funding in Europe and USA.

Experience of more than 75 healthcare transactions including divestment, M&A,

licensing, funding, business development, strategic partnering.

Dr. Bill Mason

13

B.S. in Business Management from Long Island University and M.B.A. from

Columbia University.

Founder, President and CEO of Fritzsche, Pambianchi & Associates and

Owen, Pambianchi & Associates.

Co-founder of The Immune Response Corporation (the first biotech company

to achieve $1 billion in market cap), Cortex Pharmaceuticals, Odyssey

Nutriceutical Sciences, and Array Medical.

Founder of The Medical Business Publishing Corporation.

Co- Founder of The Sage Group.

Wayne Pambianchi

14

Fordham University, degree in Pharmacy and Iona College, MBA

President and CEO of Osteologix, 2004 until 2007, Questcor, 1999 until 2004 and

RiboGene, 1993 until 1999. IPOed the latter two companies.

Co-founded in 1989, took public and was CEO of Interneuron (Indevus)

Held marketing, sales, finance and business development positions with Sandoz,

Hoffmann-LaRoche and Johnson & Johnson

Vice President of Business Development and Strategic Planning for the Critical

Care Division for and American Hospital Supply Corporation

Senior Vice President & General Manager for Pharmaceuticals and Biochemicals

at Genzyme from 1985 through 1989

Four Biotech company IPOs

Charles J. Casamento

15

B.S. in Chemistry from Washington & Lee University, M.B.A. from the Amos Tuck

School of Business Administration, Dartmouth College.

President and Chief Executive Officer of OncoTherapeutics.

President and CEO of Immunetech Pharmaceuticals (Dura), Inc., of San Diego.

Director of Marketing, Gynecological Products, at G.D. Searle, Product Manager

at Pfizer Laboratories.

Founding Vice Chairman of the BCNJ. Chairman.

Gordon Ramseier

16

Princeton University AB in Chemistry, Masters degrees in Chemical

Engineering and Industrial Management from MIT.

President and Chief Operating Officer, Hemispherx BioPharma.

Vice President, Business Development at Enzon, Inc.

Founder and Chief Executive Officer at i-STAT Corporation.

Vice President of Engelhard Industries.

Vice President and General Manager at Halcon International.

R. Douglas Hulse

17

Ph.D. in Immunochemistry from Temple University

Senior positions in R&D, Marketing, Technological and Strategic Planning at

Johnson & Johnson.

Director of Technical Planning at Becton-Dickinson.

General Manager of the Biomedical Division at New England Nuclear.

Scientific Advisory Boards of the State University of New York at Stony Brook and the

University of Utah.

Trustee of Federal Trade Commission.

Daniel Tripodi, PhD

18

Provides private contract services to companies in the pharmaceutical,

biotechnology and diagnostics industries.

Specializes in marketing and promotional programs: direct to consumer marketing,

promotions, seminar/group interactions, peer influence marketing and market

research.

Conducts analyses of acquisition and partnering opportunities.

Co manages alliance and acquisition transactions.

Bob worked for The Upjohn Company, Beckman Instruments and American

Diagnostics Corporation in sales, marketing, marketing management and strategic

planning positions.

Bob has a B.S. degree in Biology and Chemistry and has completed graduate-level

work in neuro-pathology

Robert Nance

19

Based in Beijing and Shanghai

PhD in medicine

Represents Sage on biopharma and medtech projects in Asia

Strong background in venture capital activities (Sofinnova Ventures China)

and business development in the CRO space with Quintiles

Strong knowledge and network in Chinese, Japanes and Asian markets

Dr. Yoshinaga speaks fluent English, Japanese and Chinese

Dr. Chika Yoshinaga - China

20

Senior Directors and Alliance Partners

21

Yoshi Mizuta, President, Waterfield HealthCom, Ltd (Japan)

40 years experience in the healthcare industry

Managing Director, International as well as Managing Director, Marketing & Sales

and Managing Director, R&D Planning for Tsumura & Company from 1993 to

2000

From 1989 to 1993 he was Vice President, Marketing and Sales, for Searle

Yakuhin Company

From 1988 to 1989 he was Vice President, Business Development Japan for

Monsanto/G.D. Searle

From 1964 to 1988 filled several positions in Ono Pharmaceuticals, covering

Project Coordination, Business Development & Licensing, Marketing and

Accounting & Finance.

B.A. in Business Administration from Rikkyo University in Tokyo and attended

UCLA Graduate School of Management in Medical Marketing

Yoshi Mizuta, Alliance Partner Japan

22

MediGlobe, Ltd.

Entrepreneurship and consultancy in life sciences.

Developed and sold patented technologies: pharma, devices, nutraceuticals.

Managed and consulted to start-up companies in the field.

Initiated and conducted various Israeli conferences in medical, cosmetic and

food topics:

The Israeli conference for clinical trials

The Israeli conference for quality and regulatory in life sciences

The Israeli conference for fund raising and technology transfer.

MediGlobe, Alliance Partner Israel

23

Economist with over 30 years experience in the pharmaceutical industry attaining

senior positions in international marketing and business development.

Built and led business intelligence units and senior executive decision support

teams for major pharmaceutical companies.

Produces 'value creation" strategies to drive M&A, product development, and

commercialization.

Works closely with stakeholders to identify value and articulate the 'value

proposition' to facilitate investment decisions and collaboration.

Advanced degrees in Economics and International Affairs (Intelligence) from

Columbia University.

American with extended work and study related experience in Europe and Asia.

Based in Israel 15 years as Senior Director with Teva's business development and

senior executive teams. Maintains close contact and visibility with bio/pharma and

academia in Israel.

In a unique position to leverage extensive professional networks that emanate from

Israel to Eastern Europe and South Asia (India).

Harris (“Jeb”) Gollin, Senior Director

24

Principal in Delta Capital & Research, LLC (DC&R), based in Boston.

DC&R provides financial advisory and strategic consulting services for start-up and growth

companies in the healthcare information and medical technology field.

Typical engagements include seed capital and private placement support, product line

analysis, market research, and operations management in conjunction with financing

strategy, partnering and M&A counsel.

Satish takes an active role in DC&R's venture capital portfolio of 12 start-ups, and was

instrumental in the The PenChart Corp., an online EMR vendor, to Pfizer Inc.

Was engaged with Schroder Venture Life Sciences Funds as a Venture Partner.

Advisor to Cornerstone Partners, a West-Coast based healthcare IT M&A boutique.

Board member of Superior Consultant Holdings Corp. and PMR Corp.

Satish spent a decade as a Wall Street research analyst, starting with Punk, Ziegel and

Knoell (where he pioneered investment coverage of healthcare information technology as

a unique research sector), and ending with Jefferies & Company and SG Cowen.

He began his career in Sales & Marketing in 1977 with India's IT pioneer, HCL.

Satish received his B.A. in Economics from the University of Delhi, a Post-Graduate

Diploma in Marketing from the Indian Institute of Management, Calcutta, and M.B.A. in

Finance from the Stern School, New York University

Satish Tyagi, Senior Director

25

Mr. Kazo has over 25 years of experience in the biopharmaceutical sector as a senior

executive, corporate officer and scientist, with extensive business development, strategic

planning, corporate financing and marketing experience in the global healthcare arena.

He has been responsible for raising over $250 million in capital from international investors,

including leading efforts in three successful IPOs.

Mr. Kazo was a Founder of Enzon, Inc., the pioneering drug delivery company that created

PEGylation technology. As VP Sales and Marketing, he launched the company's first two

products and including PEG-Intron A, which now generates over $2 billion annually.

Mr. Kazo built and managed a highly successful business development and licensing team.

Seven PEGylated products currently are on the market that have collectively generated over

$25 billion in sales.

Subsequently, Mr. Kazo joined Focal, Inc. (now a unit of Genzyme) as Vice President Corporate

Development, and helped take this biomaterials company public on NASDAQ.

Mr. Kazo then became Chief Business Officer, US General Manager, and Board member at

XTL Biopharmaceuticals, Inc. In addition to establishing and heading its US operations and

bringing the company public on the London Stock Exchange, Mr. Kazo established a series of

licenses and collaborations with leading biopharmaceutical companies in the hepatitis field.

Most recently he was Chief Business Officer at Activbiotics, Inc., a private anti-infective and

cardiovascular company. And Chairman of Prolong Pharmaceuticals.

Glenn Kazo, Senior Director

26

Medically qualified, with degrees from University of Birmingham (UK) Medical School.

Strong background in early stage venture capital, with multinational pharmaceutical industry

experience both in Europe and the USA.

Expertise in founding, growing and exiting biotechnology/life science businesses.

Awarded the Order of the British Empire (OBE) in the Queen’s Birthday Honors in June 2008

for services to innovation and technology.

Member of the UK Society of Investment Professionals.

Catherine has previously worked as Director for Medical Affairs UK for Farmitalia Carlo Erba

and Senior Director Medical Affairs, Europe, for DuPont Pharmaceuticals.

A Founder of the Cambridge Gateway Fund, a UK-based venture capital fund where she led

the healthcare team in a number of investments and was an investment adviser approved by

the UK Financial Services Authority.

Numerous board positions of early stage healthcare companies.

Chief Executive of Aitua, a private investment company specializing in the commercialization

of intellectual property in the life science sector.

CEO, Oval Medical, a drug delivery and formulation business

Served as a Member of the UK Department of Trade and Industry’s Technology Strategy

Board.

Dr. Catherine Beech M.B. ChB, OBE

27

The Sage Approach

28

Relevance of Sage

We know the needs of companies in terms of markets and growth

by acquisition and licensing

We know the needs of customers in these healthcare markets

Sage knows the industry and the industry fundamentals as well as

the industry participants and has decades of deal making

experience

We have strong working relationships with Corporate and VC

investors worldwide

We know how to create shareholder value through the right deals

with the right partners

We have extensive M&A/Licensing experience and a strong track

record in identifying targets and consummating deals

29

Sage Outline Terms

Fees for transactions normally have two or three components to be

negotiated and agreed with our clients:

A monthly fee of typically €5-10k ($7.5 – 15k), sometimes weighted to

the start of the program

A success fee based on the value of the transaction (typically a

percentage related to transaction size or incremental)

Options or warrants (where appropriate) to mitigate above fees are a

welcome component of remuneration

Expenses subject to client approval

Fees for strategic assignments, valuations, due diligence or market

assessment are normally fixed fees

30

The Sage Process – Pre Engagement

We talk and meet with you on site to clearly understand your objectives

and underlying principles

For clarity, we write a proposal for your company. This sets out:

Background to the assignment and associated issues

The objectives

The workplan

Timetable

The core team to be assigned and biographies thereof

Confidentiality provisions

Terms & conditions

Fees for strategic assignments are normally fixed fees

31

The Sage Process – Post Engagement

We gather information and meet for 1-3 days to understand your

company, technology and objectives and define strategy

We draft an Information Memorandum (IM) including

Technology, IP, Market, Products and Services, Competition,

Financial Data

Unique Selling Points and Value Drivers

We compile with you a Target List for discussion focused on our network

of industry contacts

We work with you to prepare corporate presentation material

We assist you in compiling background information for confidential

transmission under CDA, due diligence/data room use

We work with you in partnership throughout deal formation, term sheet

negotiation, value discussions and final closure

32

Prepare IM with appropriate positioning

In parallel, research and analyse industry to identify targets and prepare draft “control sheet”

Assist with corporate presentation materials and data room

Distribute finalized IM to identified targets

Follow Up and generate interest among targets

Select interested targets

Sign CDA for in depth analysis of interested targets

Coordinate technical and business meetings (face to face or teleconferences)

Obtain term sheet from interested targets

Presentation to and discussion with Board

Negotiation

Agreement

The Sage Process – Post Engagement

33

Positioning of Opportunity

Aim – Generate Interest and Identify Value Drivers

Initially reviewed by Business Development/Licensing Teams

Technology review

Non-confidential

“Wet appetite”

Commercializable

Role of Information Memorandum

34

We work with our clients to understand their priorities and

criteria for new incoming products which they might with to

license or acquire

We prepare a corporate overview of our client’s business as

an information tool for targets

We search our global networks and databases for assets and

products and then rank these in line with our client’s needs

We assess the likelihood of getting a deal done and negotiate

the right terms in conjunction with our client’s BD team

We conduct discussions and negotiations with targets having

identified the top priorities agreed with our client and submit a

term sheet as well as leading due diligence if required

Finally, we work to close the deal!

Buyside Acquisition Searches

35

Clients

36

Representative Sage Clients Since 1995

3i Group

Acolyte Biomedica

Actavis (formerly Watson)

Advancell

Alfacell

American Biogenetic Sciences

AndCare

Anergen

Atrix

Aurogen

Aventis

Bayer Pharmaceuticals

Baxter

Beleaf

Berkley Heart Labs

BioCancell

BioCryst

Biotrin

BMD

Brahms

B. Braun

Emisphere

Enzon

Escend

Federal Trade Commission

(Trustee)

Fluxome

Focal, Inc.

Gamma-A

GEM Pharmaceuticals

GLYKO, Inc.

Gynetics

Haemacure

Harbourvest

HCP

Hemispherx

Hycor

Imaginot

Immunomedics

Immune Response Corp.

IRM

Isofol

KPL

BMT

Brenner Securities

Bristol-Myers Squibb

Canbex Pharma

Carr Separations

Carter Wallace

Celgene

Centeon

Chordate Meical

Chromagen

CLI Oncology

Closure Medical

CNSystems

Coller Capital

Connaught

Daewoong

Delcath

Devco

Discovery Labs

Drug Royalty

Dura

e2V Technologies

Echo Pharmaceuticals

37

Representative Sage Clients Since 1995

La Jolla Pharmaceuticals

Lifecodes

Luminex

Luzitin

McKinley

Medical Science Partners

Mediglobe

Microprevention Tests

Mountain View Pharma

Natimmune

Neuromedica

NJ Economic Dev Auth

Nitromed

NorChip

Nova Molecular

Noven

Odyssey Therapeutics

Omega

Opticul

Optimata

Palau Pharma

Pennsylvania State Univ.

Pentech

Tanabe Seiyaku

Tandem

Targeted Genetics

Thermo BioStar

3-D Pharma

Teijin

Teva

Toray-Fuji Bionics

Toolgen

Transgenic Products

Transmolecular

Trinity Biotech

Ultrafem

Univ. Cambridge/MIT

U.S. Biomaterials

Veritas

Vestar

Visus

WelGene

Zeneca

Zeus

Phairson, Ltd.

Pharmaply

Pivotal

Pluristem

PneumaCare

Precious Cells Group

Polish Government

Prolong Pharmaceuticals

Regenerys

Response Biomedical

RGene Therapeutics

Rohm & Haas

Samyang

Scienion

SK Corporation

Small Molecule Therapeutics

Societe General

Solasia

Soros Fund Management

Southcoast Capital

Spherium Biomed

Supratek

Surgicon

38

Sage Group Transaction Experience

39

Mergers/Acquisition/Divestitures

Sold gene diagnostics IP from Replicon to Biokit

Sold Cytocell to Oxford Gene Technology

Sold Palau Pharma assets to Actavis (Watson)

Sold Murex Diagnostics to SYVA for $10 million

Sold Cenix’s siRNA diagnostic business to (now) Life Technologies.

Sold Cytomyx to Serologicals (now Merck Millipore) for $7 million

Sold Life Science Resources to Perkin Elmer for $25 million.

$50 million acquisition in cardiovascular device field for a major pharma.

A $35 million acquisition by Fisons of CMS, a U.S.distributing organization

Advised a small, critical care company to grow from less than $2 million in revenue to

over $15 million and facilitated its sale to ThermoElectron for $35 million.

Sold public biotechnology company, in Chapter 11, to Baxter for $10 million

Sold Biorex (Hungarian) to CytRx for niche neuro (ALS) $3 million

Sold Focal, Inc (public) to Genzyme BioSurgery for $15 million

Sold Andromed (Canadian diagnostic device company) to Masimo for $3 million

Sold McKinley Medical’s drug infusion business to Wi Medical

Sale of Astex to Otsuka for ~ $900 million

40

Mergers/Acquisition/Divestitures

Advised sale of RGene Therapeutics to Targeted Genetics for $25 million

Advised Noven in the acquisition of JDS Pharmaceuticals or $125 million.

Acquired Genex for Enzon

As VP of Engelhard Industries acquired $15 million business from DuPont.

At Genzyme divested a non-strategic research biochemical business.

Merged with a public corporation to form Questcor Pharmaceuticals.

Completed merger of Osteologix a public shell company.

As CEO of Questcor, acquired Acthar from Aventis.

Acquired Dura as start if Immunetech’s strategic redirection.

Sold Array Medical to Helena for ~$10 million(upfront+15 year royalty)

Sold McKinley Medical (drug delivery) to WI Medical

Acquired Clark Labs for Trinity Diagnostics for $6.2 million.

Acquired Cogent Diagnostics Scottish diagnostics for Hycor BioMedical.

"Clandestinely" acquired key IP to protect key Teva MS asset

41

Partnering/Alliances/JVs

At Interneuron, partnered the marketing of Redux with American Home Products.

At Roche served on a three man committee that negotiated and concluded the

first Roche/Genentech agreement :co-development of Alpha Interferon.

For Sandoz, negotiated an Alza (now J&J) drug delivery development agreement.

Sandoz, acquired the rights to Restoril from American Home Products.

At Sandoz acquired rights to Pamelor a marketed antidepressant product from Eli

Lilly.

Consummated an $80 million strategic alliance between SK Pharma and J&J.

Closed a $60 million strategic alliance between SK pharma and Cordis (J&J).

Closed a $60 million alliance between Biocryst and J&J for an influenza drug.

Closed strategic alliance for Hemispherx for Latin America with GP Pharm.

Closed alliance for Hemispherx Biopharma for sales and marketing and

distribution of one of its product in the US with Armada Healthcare

Completed a corporate alliances for Biotrin plc.

For Hemispherx closed collaborative agreement with Biken for nasal flu vaccine.

42

Partnering/Alliances/ JVs

For Enzon partnered with Schering for PEG-Intron A

As Director of Business Planning at Halcon, led the team establishing the largest

chemical joint venture in Japan in excess of $100 million.

For Ribogene completed corporate collaborations and R&D collaboration

agreements with Abbott Labs, Dainippon and Roberts Pharmaceuticals.

At Questcor, negotiated a R&D development agreement with Dainippon to

acquire and develop Questcor’s anti-bacterial products; an R&D development

agreement with Tularek to acquire and develop Questcor’s anti-fungal products;

and with Rigel to acquire and develop Questcor’s anti-viral products.

Negotiated the merger of RiboGene and Cypros; the company was re-named

Questcor.

At RiboGene, negotiated R&D partnership with Abbott labs to co-develop/market

RiboGene anti-fungal products, R&D partnership with Roberts Pharmaceuticals to

develop a RiboGene gastrointestinal product, and an R&D partnership with

Dainippon to co-develop and market RiboGene's anti-bacterial products.

At Interneuron, acquired rights to Redux an appetite suppressant, from Servier.

43

Licensing

Licensed Oncospar to Rhone Poulenc Rorer

Closed a licensing transaction between Nitromed and British Oxygen Corporation

(Ohmeda).

Structured the first licenses for Luminex Corporation.

Closed a license option agreement for an Israeli life science company with major

research reagents company.

Licensed NatImmune’s recombinant protein property to Enzon for $100M in

milestones and+ royalties).

For Nitromed licensed Nitric Oxide for stents Cordis (J&J) for $10M upfront, R&D

funding; total $60M

For MicroDose licensed inhalation delivery to Novartis and 3M

For MicroGenomics licensed Enzynomics for drug discovery for $1M upfront,

R&D funding, and 20% equity

For MicroDose licensed BMS an Inhaled drug delivery for $1M; R&D funding;

milestones; total $20 million

SK Pharma licensed to J&J a neurologic Compound for $5M upfront; R&D:

milestones: total $40M

44

Operating and Board Positions

President and CEO of Osteologix from October 2004 until April, 2007.

Senior VP & General Manager for Pharmaceuticals and Biochemicals at Genzyme.

Board member at numerous companies including Vivus, Inc.; Cortex Pharmaceuticals,

Astex Pharmaceuticals ; International Stem Cell Corporation; Sphere Medical; Amarin

Inc; Orthomimetics; Regenerys; PneumaCare, Ranier Technology.

President and Chief Executive Officer of OncoTherapeutics

President and CEO of ImmuneTech Pharmaceuticals (later Dura Pharmaceuticals), Inc.,

of San Diego.

Headed the original J&J division established to develop technology emanating from

Scripps.

Served on Scientific Advisory Boards of the State University of New York at Stony Brook

and the University of Utah as well as the Biotechnology Advisory Committee for the

Department of Commerce and the Immunodiagnostic Committee of the National

Committee of Clinical Laboratory Standards.

45

Start-Ups

Founded i-STAT which was sold to Abbott for in excess of $390 million.

Built four ventures into multi-million dollar businesses at Engelhard.

Co-founded and took public, Interneuron Pharmaceuticals (Indevus/Endo) which

eventually reached a $1.6 billion market valuation.

Co-Founded The Immune Response Corporation, the first biotech company to reach $1

billion in market capitalization.

Co-Founded Cortex Pharmaceuticals.

Assisted in the start-up of Fibritek and served as President and CEO.

Co Founded & Raised >$ 5 million for Microgenomics, natural microorganisms.

Founder Life Science Resources which was divested to Perkin Elmer

Founder Orthomimetics, raised £7M and divested post CE-marking to Tigenix

Founded Array Medical with products for acute patient care monitoring.

Founded Odyssey Nutraceuticals, served as Chairman and President and helped raise

over $5 million.

Director of Teraview, and advised on spinout from Toshiba Ventures

Led spinout of Sphere Medical from Siemens Ventures

46

Analysis

Quick market assessment of new formulation of ADHD drug.

Strategies assessment of large pharma’s wound care portfolio and strategic

direction.

Strategic assessment of large pharma's women's health care business.

Acqusition due diligence of diversification for company with failed lead product

with cash.

Assessment of orphan drug acquisition opportunities.

Physician survey to determine “chain of care” for immunological disease with no

present treatment.

Market analyses gained by interviewing senior marketing executives in women’s

healthcare.

Acquisition searches in oncology and neurology.

Strategic analysis of optimal diversification.

Partner search and analysis for oncology company.

Establishment of FDA strategy and clinical study program for novel IVD company.

46

47

Contact Details

US Corporate Office European Corporate Office

The Sage Group Inc.

1802 Route 31 North, #381

Clinton, NJ 08809

USA

Attn: Wayne Pambianchi

Phone: +1 908 2319644

Cell: +1 908 2306170

Fax: +1 908 2319692

wpambianchi@sagehealthcare.com

Sage Healthcare Ltd.

The Old Black Barns

Lord’s Lane

Ousden, Newmarket CB8 8TX

Suffolk UK

Attn: Dr. Bill Mason

Phone: +44 1638 500775

Cell: +44 7785 950134

wtm@sagehealthcare.com

www.sagehealthcare.com